Grzegorski, Steven J.
Hu, Zhilian
Liu, Yang
Yu, Xinge
Ferguson, Allison C.
Madarati, Hasam
Friedmann, Alexander P.
Reyon, Deepak
Kim, Paul Y.
Kretz, Colin A.
Joung, J. Keith
Shavit, Jordan A.
Funding for this research was provided by:
National Heart, Lung, and Blood Institute (T32 HL125242, R01 HL125774)
National Institutes of Health (T32 GM007863, R01 GM088040)
American Heart Association (Predoctoral Fellowship)
Natural Sciences and Engineering Research Council of Canada (RGPIN-2017-05347, RGPIN-2017-04692)
Hemophilia of Georgia (Clinical Scientist Development Grant)
National Hemophilia Foundation (Career Development Award)
Bayer (Hemophilia Awards Program)
Article History
Received: 1 October 2019
Accepted: 22 January 2020
First Online: 4 March 2020
Competing interests
: J.A.S. has been a consultant for Bayer, Shire, CSL Behring, Spark Therapeutics, and NovoNordisk. J.K.J. has financial interests in Beam Therapeutics, Editas Medicine, Excelsior Genomics, Pairwise Plants, Poseida Therapeutics, Transposagen Biopharmaceuticals, and Verve Therapeutics (f/k/a Endcadia). J.K.J.’s interests were reviewed and are managed by Massachusetts General Hospital and Partners HealthCare in accordance with their conflict of interest policies. J.K.J. is a member of the Board of Directors of the American Society of Gene and Cell Therapy. J.K.J. is a co-inventor on various patents and patent applications that describe gene editing and epigenetic editing technologies. Additional authors have no competing interests as defined by Nature Research, or other interests that might be perceived to influence the results and/or discussion reported in this paper.